Insulin icodec: A novel once‐weekly treatment for diabetes
Diabetic Medicine2024Vol. 41(10), pp. e15414–e15414
Citations Over TimeTop 13% of 2024 papers
Hannah Schaffner, Jordyn Wiener, Amanda DeLuca, Ariana Genovese, Alexander Deeb, Wasim Deeb, Mae Sheikh‐Ali, David Sutton, Ashwini Gore, Jason Berner, Jessica Huston, Rebecca F. Goldfaden
Abstract
As a once-weekly alternative to daily basal insulin, icodec is expected to improve patient adherence and satisfaction, reducing the required number of injections per year from 365 to 52 and providing a dosing option potentially attractive to a wide range of insulin users. However, clinical data suggest a notable risk of hypoglycaemia with weekly icodec administration, especially in individuals with type 1 diabetes.
Related Papers
- → Exogenous Glucocorticoids and a High-Fat Diet Cause Severe Hyperglycemia and Hyperinsulinemia and Limit Islet Glucose Responsiveness in Young Male Sprague-Dawley Rats(2013)47 cited
- → The Paraventricular Nucleus of the Hypothalamus Has a Major Role in Thyroid Hormone Feedback Regulation of Thyrotropin Synthesis and Secretion(1990)53 cited
- → Modulation of Adipoinsular Axis in Prediabetic Zucker Diabetic Fatty Rats by Diazoxide(2004)39 cited
- Susquehanna Chorale Spring Concert "Roots and Wings"(2017)
- → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)